Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Burn

Showing results (121-130 of 128) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 128 results.
Journal of Medicinal Chemistry|October 14, 2005
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimeticsAndrew P Combs, Eddy W Yue, Michael Bower, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Science (New York, N.Y.)|June 5, 1999
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteinsM D Tortorella, T C Burn, M A Pratta, et al.
Journal of Medicinal Chemistry|January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancerWenqing Yao, Jincong Zhuo, David M Burns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
The Journal of Clinical Investigation|March 1, 2021
Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathyNajim Lahrouchi, Alex V Postma, Christian M Salazar, et al.
Pageof 13

Showing results (121-130 of 128) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 128 results.
Journal of Medicinal Chemistry|October 14, 2005
Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimeticsAndrew P Combs, Eddy W Yue, Michael Bower, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
Science (New York, N.Y.)|June 5, 1999
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteinsM D Tortorella, T C Burn, M A Pratta, et al.
Journal of Medicinal Chemistry|January 30, 2007
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancerWenqing Yao, Jincong Zhuo, David M Burns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2018
The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination StrategiesMatthew C Stubbs, Timothy C Burn, Richard Sparks, et al.
Nature|September 1, 2022
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
Nature|August 10, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg, Jinhyuk Bhin, Julia Yemelyanenko, et al.
The Journal of Clinical Investigation|March 1, 2021
Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathyNajim Lahrouchi, Alex V Postma, Christian M Salazar, et al.
Pageof 13